<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CLADRIBINE</span><br/>(cla'dri-been)<br/><span class="topboxtradename">Leustatin<br/></span><b>Classifications:</b> <span class="classification">antineoplastic; antimetabolite, purine antagonist</span><br/><b>Prototype: </b>6-mercaptopurine<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Cladribine is a synthetic antineoplastic agent with selective toxicity toward certain normal and malignant lymphocytes and
         monocytes. It accumulates intracellularly, preventing repair of single-stranded DNA breaks and ultimately interfering with
         cellular metabolism and DNA synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Cladribine is cytotoxic to both actively dividing and quiescent lymphocytes and monocytes, inhibiting both DNA synthesis and
         repair.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hairy cell leukemia.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Advanced cutaneous T-cell lymphomas, chronic lymphocytic leukemia, non-Hodgkin's lymphomas, acute myeloid leukemia, autoimmune
         hemolytic anemia, mycosis fungoides.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cladribine; pregnancy (category D).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic or renal impairment. Safety and efficacy in children not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hairy Cell Leukemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.09 mg/kg/d by 7 d continuous infusion<br/><br/><span class="indicationtitle">Chronic Lymphocytic Leukemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.1 mg/kg/d by 7 d continuous infusion <i>or</i> 0.0280.14 mg/kg/d as 2 h infusion for 5 consecutive d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Solutions for cladribine should not be mixed with any other IV drugs or additives, nor administered through an IV line used
            for other drugs or solutions.
         </li>
<li>Use disposable gloves and protective clothing when handling the drug.</li>
<li>Wash immediately if skin contact occurs.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion (single daily dose):</span>  IV infusion (7-day dose): The calculated dose of cladribine is injected into an infusion reservoir using a 0.22 micron filter.
                  An amount of bacteriostatic NS is added through a 0.22 micron filter to bring the total to 100 mL. (Note: reservoir usually
                  prepared by the pharmacist.)  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion (single daily dose):</span>  Distribute evenly over ordered time (i.e., 2 h or 24 h).   <span class="methodtype">IV infusion (7-day dose):</span>  Give through a central line and control by a pump device (e.g., Deltec pump) to deliver 100 mL evenly over 7 d.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span> Do not mix with any other diluents or drugs. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Diluted solutions of cladribine may be stored refrigerated for up to 8 h prior to administration.</li>
<li>Store unopened vials in refrigerator (2°8° C/36°46° F), and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead"> GI:</span> Nausea, diarrhea. <span class="typehead">Hematologic:</span>
<span class="speceff-both">Myelosuppression (neutropenia)</span>, <span class="speceff-common">anemia,</span> thrombocytopenia. <span class="typehead">Metabolic:</span>
<span class="speceff-common">Fever.</span>
<span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">Urogenital:</span> Elevated serum creatinine. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Additive risk of bleeding with <span class="classification">anticoagulants</span>, <span class="classification">nsaids</span>, <span class="classification">platelet inhibitors</span>, <span class="classification">salicylates</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> Therapeutic effect 10 d to 4 mo. <span class="typehead">Duration:</span> 725+ mo. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> In malignant leukocytes, cladribine is phosphorylated to form its monophosphate and triphosphate forms, presumably its active
      forms, which are subsequently incorporated into cellular DNA. <span class="typehead">Half-Life:</span> Initial 35 min, terminal 6.7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs during and after drug infusion. Fever (&gt;100° F) is common during the 5th to 7th day in patients with
            hairy cell leukemia, and severe fever (&gt;104° F) may develop within the first month of therapy.
         </li>
<li>Lab tests: Frequent hematologic studies; periodic serum creatinine and liver function tests.</li>
<li>Closely monitor hematologic status; myelosuppression is common during the first month after starting therapy.</li>
<li>Monitor for and report S&amp;S of infection. Note that within the first month, fever may occur in the absence of infection.</li>
<li>With high doses of cladribine, monitor for neurologic toxicity (paraparesis/quadriparesis) and acute nephrotoxicity.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be fully informed regarding adverse responses to the drug.</li>
<li>Understand the need for close follow-up during and after treatment with the drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>